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Abstract
Background: Epstein-Barr virus (EBV)-encoded LMP1 protein is commonly expressed in nasopharyngeal carcinoma 
(NPC). LMP1 is a prime candidate for driving tumourigenesis given its ability to activate multiple signalling pathways 
and to alter the expression and activity of variety of downstream targets. Resistance to TGFβ-mediated cytostasis is one 
of the growth transforming effects of LMP1. Of the downstream targets manipulated by LMP1, the induction of Id1 and 
inactivation of Foxo3a appear particularly relevant to LMP1-mediated effects. Id1, a HLH protein is implicated in cell 
transformation and plays a role in cell proliferation, whilst Foxo3a, a transcription factor controls cell integrity and 
homeostasis by regulating apoptosis. The mechanism(s) by which LMP1 induces these effects have not been fully 
characterised.
Results: In this study, we demonstrate that the ability of LMP1 to induce the phosphorylation and inactivation of 
Foxo3a is linked to the upregulation of Id1. Furthermore, we show that the induction of Id1 is essential for the 
transforming function of LMP1 as over-expression of Id1 increases cell proliferation, attenuates TGFβ-SMAD-mediated 
transcription and renders cells refractory to TGFβ-mediated cytostasis. Id1 silencing in LMP1-expressing epithelial cells 
abolishes the inhibitory effect of LMP1 on TGFβ-mediated cell growth arrest and reduces the ability of LMP1 to 
attenuate SMAD transcriptional activity. In response to TGFβ stimulation, LMP1 does not abolish SMAD 
phosphorylation but inhibits p21 protein expression. In addition, we found the induction of Id1 in LMP1-expressing 
cells upon stimulation by TGFβ. We provide evidence that LMP1 suppresses the transcriptional repressor ATF3, possibly 
leading to the TGFβ-induced Id1 upregulation.
Conclusion: The current data provide novel information regarding the mechanisms by which LMP1 suppresses TGFβ-
induced cytostasis, highlighting the importance of Id1 in LMP1 mediated cell transformation
Background
The Epstein-Barr virus (EBV)-encoded latent membrane
protein (LMP1) is commonly expressed in nasopharyn-
geal carcinoma (NPC) and is believed to play important
role in NPC pathogenesis [1]. LMP1 is an oncogenic pro-
tein, inducing lymphomagenesis in transgenic mice and
transforming rodent fibroblasts in vitro, rendering them
tumourigenic in vivo. In vitro studies show that LMP1 is
essential for EBV immortalisation of primary B cells, and
c a n  i n d u c e  a  s t a t e  o f  c e l l  a c t i v a t i o n  i n  B  l y m p h o m a -
derived cell lines. In epithelial cells, LMP1 increases cell
proliferation, promotes anchorage independent growth,
protects cells from apoptosis, induces an epithelial-mes-
enchymal transformation, promotes cell invasion and
perturbs epithelial cell differentiation [2,3]. LMP1 is an
integral membrane protein comprising a 24 amino acid
N-terminal cytoplasmic domain, six transmembrane
spanning domains connected by short reverse turns, and
a 200 amino acid C-terminal cytoplasmic domain. LMP1
functions as a constitutively active viral mimic of CD40,
engaging multiple signalling pathways which include
NFκB, PI3K/Akt, ERK-MAPK/JNK, JAK/STAT, and p38/
MAPK pathways to alter various gene expression pro-
grams [2,3].
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Of the signalling pathways activated by LMP1, PI3K/
A k t ,  E R K - M A P K  a n d  N F κ B  s i g n a l l i n g  p a t h w a y s  h a v e
been shown to induce phosphorylation and inhibit the
activity of the Forkhead box class O (Foxo) transcription
factors [4]. Foxo family members including Foxo1,
Foxo3a, Foxo4 and Foxo6 activate or repress genes such
as Bim, p27kip and cyclin D1, which regulate apoptosis or
cell-cycle progression respectively. Foxo proteins are sub-
ject to regulation through phosphorylation, resulting in
nuclear to cytosolic export and subsequent degradation.
Foxo protein deregulation is associated with cell prolifer-
ation, altered differentiation and an accumulation of
DNA damage findings suggestive of a role in driving car-
c i n o g e n e s i s  [ 4 , 5 ] .  A l t h o u g h  a  n u m b e r  o f  F o x o  t a r g e t s
have been identified, a recent study in leukemic cells has
shown that Foxo3a negatively regulates the transcription
of Inhibitor of DNA binding 1 (Id1), a member of the
helix-loop-helix (HLH) proteins [6]. The Id1 protein is
unable to bind DNA, but it functions as dominant nega-
tive regulator, inhibiting the binding of other basic HLH
(bHLH) transcription factors to their target genes. Over-
expression of Id1 has been observed in a variety of can-
cers where it may contribute to a variety of cellular func-
tions that include cell proliferation, resistance to
apoptosis, angiogenesis, invasion and inhibition of termi-
nal cell differentiation [7].
Cell proliferation and differentiation are tightly regu-
lated by growth promoting factors and growth inhibitory
factors. TGFβ functions as a prototypical tumour sup-
pressor, inhibiting the growth of untransformed epithe-
lial, endothelial and lymphoid cells. In keeping with its
role as a tumour suppressor, resistance to TGFβ is
regarded as one of the crucial steps in malignant progres-
sion [8,9]. TGFβ-mediated cell inhibition is induced by
S M A D - d e p e n d e n t  r e g u l a t i o n  o f  T G F β  t a r g e t  g e n e s .
LMP1-expressing fibroblasts and EBV-infected lympho-
cytes are reportedly refractory to TGFβ-mediated growth
arrest [10,11]. Although several reports have demon-
strated a role for NF-κB in modulating the transcriptional
activity of SMAD complexes, the mechanism(s) by which
LMP1 confers resistance to TGFβ are not fully resolved
[12,13].
In this study, we report that LMP1 inactivates the func-
tion of Foxo3a leading to upregulation of Id1. The induc-
tion of Id1 by LMP1 confers cellular resistance to TGFβ
through a mechanism involving inhibition of TGFβ-
SMAD-mediated transcription. In addition, we show that
LMP1 inhibits the expression of ATF3, a transcription
repressor that co-operates with SMAD to mediate Id1
suppression. By inhibiting ATF3 expression, LMP1
relieves the suppressive effect of TGFβ on Id1 expression.
Results
LMP1 suppresses the expression and transcriptional 
activity of Foxo3a
LMP1 confers growth and transforming properties to
epithelial cells by activating multiple signal cascades.
These include the PI3K/Akt, ERK-MAPK and NFκB sig-
nalling pathways amongst others. Activation of these
three pathways results in suppression of the transcrip-
tional activity of Foxo3a [4]. One consequence of Foxo3a
inactivation by LMP1 is inhibition of DNA repair [14].
Here, we examine additional downstream consequences
of Foxo3a inactivation by LMP1. In keeping with previ-
ously published findings, we demonstrate that transient
e x p r e s s i o n  o f  L M P 1  i n  H E K - 2 9 3  c e l l s  s t i m u l a t e d  A k t ,
Erk1/2 and IκB phosphorylation in a dose dependent
manner and was accompanied by Foxo3a phosphoryla-
tion and protein degradation (Figure 1A) [2,14]. In agree-
ment with previously published studies, reduction of
p27kip, a transcriptional target of Foxo3a by LMP1 was
also observed [15]. An examination of a nasopharyngeal
epithelial cell line NP69 stably expressing LMP1 (NP69-
LMP1) revealed increased cytoplasmic levels of Foxo3a,
and an overall reduction in total Foxo3a and p27kip pro-
tein (Figure 1B). Stable expression of LMP1 was also
accompanied by increased phosphorylation of IκB, Akt
and Erk1/2. To examine further the effect of LMP1 on
Foxo3a-mediated transcription, luciferase assays were
performed using promoter reporter constructs of two
established Foxo3a target genes: p27kip  and Bim. As
shown in Figure 1C, transient expression of LMP1 in
HEK293 cells attenuated the activity of both promoter
reporters in a dose-dependent manner. In the reciprocal
experiment, exogenous expression of Foxo3a enhanced
the activities of both p27kip and Bim promoter reporters.
This induction was antagonised by LMP1 expression
(Figure 1D). Taken together, these data confirm that
LMP1-induced phosphorylation, nuclear translocation
and degradation of Foxo3a ablate Foxo3a transcriptional
activity in epithelial cells.
Inactivation of Foxo3a by LMP1 stimulates Id1 expression
A recent report has shown that Foxo3a downregulates
Id1 transcription [6]. This led us to investigate whether
inactivation of Foxo3a by LMP1 impacted on Id1 expres-
sion. Firstly, immunoblotting confirmed increased levels
of Id1 expression in epithelial cells expressing LMP1 (Fig-
ure 1A &1B), findings that are consistent with previously
published data [16,17]. Furthermore, transient overex-
pression of HA-tagged Foxo3a in NP69-LMP1 cells
resulted in a marked reduction in Id1 protein expression
(Figure 2A), confirming the reciprocal relationship
between Foxo3a and Id1 expression. Using an Id1 (-1695)Lo et al. Molecular Cancer 2010, 9:155
http://www.molecular-cancer.com/content/9/1/155
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Figure 1 LMP1 suppresses the expression and transcriptional activity of Foxo3a. (A) HEK-293 cells were transfected with increasing amount of 
the LMP1 vector (pSG5-LMP1) as indicated. Forty-eight hours post-transfection, cells were harvested for immunoblotting analysis. For the detection 
of Id1 and Foxo3a, cells were cultured in serum free medium for 6 hrs before harvesting. (B) Total cell lysates of NP69-pLNSX control and NP69-LMP1 
cells were analyzed by immunoblotting. For detection of cytoplasmic and nuclear proteins, cells were treated with protease inhibitor, MG132 (20μM) 
for 4 hrs prior to harvesting. Relative protein expression was calculated using densitometry with the control set at 1. (C) HEK-293 cells were transfected 
with various doses of the LMP1 expression vector (pSG5-LMP1) and reporter constructs for p27kip or Bim. (D) HEK-293 cells were transfected with var-
ious doses of GFP-Foxo3a and the p27kip or Bim promoter reporter constructs, together with 40 ng LMP1 expression vector (pSG5-LMP1) or control 
empty vector (pSG5). Cells were harvested for luciferase reporter analysis 48 hrs post-transfection. Luciferase activity was normalized to β-gal activity. 
Data shown are the mean ± s.d. of three separate experiments. The relative luciferase unit (RLU) is plotted relative to that of the reporter alone (set at 1).
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promoter reporter construct, we found that transient
expression of LMP1 augmented Id1 promoter activity in
HEK-293 cells in a dose-dependent manner (Figure 2B).
While Foxo3a inhibited the transcriptional activity of Id1
promoter, LMP1 counteracted this negative effect (Figure
2C). Foxo3a has been shown to repress Id1 transcription
through direct binding to the Id1 promoter at position -
134 to -128 bp upstream of the ATG [6]. To evaluate fur-
ther the interplay between Foxo3a, Id1 and LMP1, a
shorter Id1 promoter construct (-353) was transfected
into NP69 nasopharyngeal epithelial cells together with
increasing amounts of LMP1. As shown in Figure 2D,
LMP1 increased the luciferase activity of this shorter Id1
promoter construct. In addition, the suppressive effect of
Foxo3a on this shorter Id1 promoter element was antago-
nised by LMP1 (Figure 2E). Taken together, these data
confirm that LMP1 limits the ability of Foxo3a to repress
Id1 promoter transcription.
LMP1 induction of Id1 confers resistance to TGFβ-mediated 
cytostasis
TGFβ is a potent regulator of squamous epithelial
homeostasis acting as a tumour suppressor by inducing
cell cycle arrest. Id1 has multiple oncogenic functions
imparting resistance to TNFα and anti-cancer drug-
induced apoptosis [18]. Here, we sought to investigate
whether Id1 confers pro-survival properties in NP69
cells, a nasopharyngeal epithelial cell line that is respon-
sive to TGFβ-mediated growth inhibition [19]. Using
both cell-cycle and proliferation assays, we found that
stable expression of Id1 in NP69 cells enhanced cell pro-
liferation and overcame TGFβ-mediated G1 cell cycle
arrest (Figure 3A &3B). Inhibition of TGFβ-mediated
growth arrest by LMP1 in B cells and fibroblasts has been
reported previously [10,11]. Using an epithelial cell
model, we set out to explore whether the resistance to
T G F β  a f f o r d e d  b y  LM P 1  w a s  a s s o c i a t e d  w i t h  i n c r e a s e
expression of Id1. Firstly, NP69-pLNSX and NP69-LMP1
Figure 2 Inactivation of Foxo3a by LMP1 results in Id1 induction. (A) NP69 cells stably expressing pLNSX vector control or LMP1-pLNSX were 
transfected with a HA-tagged Foxo3a expression vector. Forty-eight hours after transfection, cells were cultured in growth factor free medium for 6 
hrs prior to immunoblotting analysis. (B) HEK-293 cells were transfected with an Id1 (-1695) promoter luciferase reporter and various doses of LMP1 
expression vector (pSG5-LMP1) or (C) various doses of Foxo3a expression vector together with 40 ng LMP1 expression vector or control pSG5 empty 
vector. (D) NP69 cells were transfected with an Id1 (-353) promoter luciferase reporter and various doses of a LMP1 expression vector (pSG5-LMP1) or 
(E) various doses of a Foxo3a expression vector together with 40 ng LMP1 expression vector or pSG5 control vector. Thirty hours post-transfection, 
cells were incubated in serum free medium for 6 hrs prior to harvesting for luciferase analysis.
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Figure 3 LMP1 induction of Id1 confers resistance to TGFβ-mediated growth inhibition. (A) NP69 cells stably expressing Id1 were treated with 
10 ng TGFβ in KSF medium (KSF) for 24 hrs prior to cell growth analysis by MMT assay (A) and cell cycle analysis by flow cytometry (B). NP69-pLNSX 
and NP69-LMP1 cells expressing pSuper.retro control or Id1 shRNA (shId1B+C) were treated with TGFβ for 24 hrs prior to cycle analysis (C) and cell 
growth analysis (D). Data shown are the mean ± s.d. from three experiments.
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cells were transduced with retroviruses containing either
individual shRNAs to Id1 (shId1B or shId1C), or both
(shId1B+C). After drug selection, the suppressive func-
tion of Id1 shRNAs in stably established cell lines was val-
idated [see Additional file 1].
Using cell cycle analysis, NP69-LMP1 pSuper.retro cells
maintained in normal KSF medium were found to con-
tain higher percentage of cells in the S and G2 phases of
the cell cycle compared to NP69-pLNSX pSuper.retro
control cells, demonstrating that LMP1 promotes cell
proliferation (Figure 3C). NP69-LMP1 pSuper.retro cells
grown in normal medium (31.1%) or in medium supple-
mented with TGFβ (30.1%) showed similar percentage of
cells in the G1 phase of the cell cycle, while the NP69-
pLNSX pSuper.retro control cells treated with TGFβ had
higher percentage of cells in the G1 phase (50.1%) com-
pared to untreated cells (38.4%). These findings confirm
the ability of LMP1 to protect against TGFβ-mediated G1
cell cycle arrest in this nasopharyngeal epithelial cell line
(Figure 3C). The role of Id1 in this response was estab-
lished as NP69-LMP1 cells expressing shRNAs to Id1
exhibited clear-cut cell cycle arrest, with 48.1% of the cell
population in the G1 phase compared to NP69-LMP1
Super.retro, where 30.1% of the cell population was in the
G1 phase (Figure 3C). This finding was further supported
by MTT cell proliferation assays. As shown in Figure 3D,
NP69-LMP1 pSuper.retro cells were relatively refractory
to TGFβ-mediated growth inhibition. However, silencing
Id1 by shRNA reduced the growth of NP69-LMP1 cells in
normal medium (-17.92%) and the growth inhibition was
increased further in the presence of TGFβ (-45.65%).
Taken together, these data confirm that Id1 plays a signif-
icant role in LMP1-mediated cell proliferation and resis-
tance to the growth inhibitory effects of TGFβ.
Id1 induction by LMP1 confers resistance to TGFβ-
mediated transcription
To determine whether Id1 confers resistance to TGFβ-
mediated cytostasis by inhibiting TGFβ-mediated SMAD
transcription, an Id1 expression vector was co-trans-
fected along with the SMAD-responsive reporter con-
struct, pGL3(CAGA) or p3Tplux into HEK-293 cells.
Twenty-four hours post-transfection, cells were subjected
to TGFβ treatment for 16 hours prior to harvesting for
luciferase reporter analysis. As shown in Figure 4A,
increased expression of Id1 resulted in a dose-dependent
reduction of TGFβ-induced SMAD transcription. This
experiment was also performed in HepG2 hepatocellular
liver carcinoma cells and NP69 nasopharyngeal epithelial
cells, where similar findings were observed [see Addi-
tional file 2]. All these results suggest that Id1 is able to
inhibit the TGFβ-SMAD-mediated transcription.
LMP1 has previously been reported to inhibit SMAD
transcription [12,13]. Here, we reveal that induction of
Id1 by LMP1 plays a direct role in this inhibition. As
shown in Figure 4B, expression of LMP1 in HEK-293 cells
suppressed TGFβ-mediated transcriptional activity of
pGL3(CAGA) and p3Tlux reporter constructs. However,
addition of Id1 shRNA to silence the expression of Id1
antagonised this suppressive effect, while scrambled
shRNA treatment showed no such effect. Similar findings
were also observed in HepG2 and NP69 cells [see Addi-
tional file 3]. The effects of Id1 silencing are similar to the
effects of Foxo3a activation, as Foxo3a has been shown to
negatively regulate the expression of Id1 [6]. Exogenous
expression of Foxo3a also antagonised the suppressive
effect of LMP1 on TGFβ-mediated SMAD transcription
(Figure 4C and see Additional file 4). In summary, LMP1
induction of Id1 participates in suppressing the TGFβ-
SMAD-mediated transcription.
LMP1 suppresses the expression of TFGβ-induced p21 and 
ATF3
We have found that LMP1 suppresses TGFβ-mediated
SMAD transcription without affecting SMAD phospho-
rylation. Over a time-course of 48 hours, TGFβ treatment
stimulated phosphorylation of the SMAD2 and SMAD3
proteins in both NP69-pLNSX and NP69-LMP1 cells as
early as 2 hours after the addition of TGFβ and high levels
of phosphorylated SMAD proteins persisted thereafter
although gradually declining by 48 hours post-stimula-
tion (Figure 5). Expression of p21 protein, a downstream
target of TGFβ who expression is required for TGFβ-
mediated cytostasis, gradually increased in NP69-pLNSX
control cells 2 hours after TGFβ treatment and reached
its peak, with almost a three fold induction, at 12 hours.
Its expression then declined to basal levels by 48 hours
post-stimulation. In NP69-LMP1 cells, a relatively mod-
est induction of p21 protein was observed upon TGFβ
treatment; however, the overall p21 protein level in
NP69-LMP1 was significantly lower compared to that in
NP69-pLNSX control cells. These findings demonstrate
that LMP1's suppressive effect on TGFβ-mediated induc-
tion of p21 is independent of SMAD phosphorylation,
suggesting that the suppressive effect of LMP1 on SMAD
transcriptional activity does not involve formation of
activated SMAD complex.
We found that expression of the Id1 protein increased
in both NP69-pLNSX and NP69-LMP1 cells 2 hrs after
TGFβ addition. Thereafter, high levels of Id1 persisted in
NP69-LMP1 cells, while in NP69-pLNSX cells, the levels
of Id1 protein gradually decreased reaching basal levels
48 hours post-stimulation. During the time course fol-
l o w i n g  T G F β  t r e a t m e n t ,  t h e  l e v e l s  o f  F o x o 3 a  d i d  n o t
change significantly in either NP69-pLNSX or NP69-
LMP1 cells although the overall levels of Foxo3a protein
were lower in NP69-LMP1 compared to NP69-pLNSX
cells. These data show that Id1 is induced in LMP1-Lo et al. Molecular Cancer 2010, 9:155
http://www.molecular-cancer.com/content/9/1/155
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Figure 4 The involvement of LMP1 induced Id1 in suppressing TGFβ downstream signalling. (A) HEK-293 cells were transfected with the 
SMAD-responsive luciferase reporter constructs: pGL3(CAGA) or p3TPlux together with various doses of an Id1 expression vector (pCDNA3-Id1). (B) 
HEK-293 cells were transfected with pGL3(CAGA) or p3TPlux and various doses of LMP1 expression vector together with Id1 shRNA (shId1B+C) or con-
trol scrambled shRNA. (C) HEK-293 cells were transfected with pGL3(CAGA) or p3TPlux and various doses of LMP1 expression vector together with or 
without a Foxo3a expression vector (pGFP-Foxo3a). Twenty-four hours post-transfection, cells were treated with 10 ng TGFβ in medium with 0.2% 
FBS for 16 hrs prior to harvesting and luciferase analysis.
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expressing cells in response to TGFβ stimulation and that
this induction is not likely associated with the expression
and/or activity of Foxo3a.
Massagué and colleagues have demonstrated that Id1 is
transiently induced by TGFβ-activated SMAD3 but long-
term TGFβ stimulation results in Id1 transcriptional
repression, which is dependent on induction of the ATF3
transcriptional repressor [20]. Here, we found that the
basal levels of ATF3 were low in NP69-LMP1 cells rela-
tive to NP69-pLNSX cells. After addition of TGFβ, the
expression of ATF3 increased in NP69-pLNSX cells at 4
hours and peaked at 12 hours, while in NP69-LMP1 cells,
ATF3 protein was slightly increased at 4 hours but was
reduced thereafter. This finding suggests that LMP1 inhi-
bition of ATF3 may prolong TGFβ-mediated induction of
Id1. The effect of LMP1 on ATF3 suppression was further
confirmed in NP69 cells, where transfection of LMP1
Figure 5 LMP1 inhibits expression of the TGFβ target genes p21 and ATF3. NP69-pLNSX and NP69-LMP1 cells were subjected to TGFβ treatment 
over a course of 48 hr prior to harvesting for immunoblotting. Total cell lysates were subjected to western blot assay. The relative signal intensities of 
detected proteins are presented in a bar chart.
LMP1
Actin
Id1
pSmad3
p21
pSmad2
Foxo3a
hr TGF (5ng/ml) 0   2   4    8  12  24  48 
pLNSX LMP1
0   2    4   8  12  24  48 
ATF3
0   2   4   8 12 24 48  0  2   4   8 12  24 48 
0   2   4   8 12 24 48  0  2   4   8 12  24 48 
0   2   4   8 12 24 48  0  2   4   8 12  24 48 
0   2   4   8 12 24 48  0  2   4   8 12  24 48 
0   2   4   8 12 24 48  0  2   4   8 12  24 48 
0   2   4   8 12 24 48  0  2   4   8 12  24 48 
pLNSX                       LMP1Lo et al. Molecular Cancer 2010, 9:155
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suppressed ATF3 protein expression in a dose dependent
manner (Figure 6).
Inactivation of Foxo3a and induction of Id1 in LMP1-
expressing NPC tumours
In an examination of primary NPC tumours (T1, T2 and
T3), which displayed strong, moderate, and weak expres-
sion of LMP1 respectively, we observed a positive corre-
lation between expression of LMP1 and that of Id1,
whereas expression of Foxo3a was inversely correlated
with LMP1 expression. For example, tumour T1 shows
strong staining for both LMP1 and Id1, but weak Foxo3a
nuclear staining. In contrast, tumour T3 showed strong
nuclear staining of Foxo3a but weak detection of LMP1
and Id1 proteins. While in the normal nasopharyngeal
epithelium (NP) which is LMP1 negative, we found weak
Id1 expression but strong nuclear Foxo3a staining (Figure
7). These data suggest that LMP1 is involved in suppress-
ing Foxo3a activity and increasing Id1 expression during
NPC progression.
Discussion
The EBV-encoded LMP1 protein is oncogenic and exerts
various transforming effects in both lymphoid and epi-
thelial cells. LMP1-mediated cellular transformation con-
fers resistance to TGFβ-mediated growth arrest and
modulates SMAD transcriptional activity [10-13]. LMP1
also increases expression of Id1, a HLH protein whose
deregulation plays a role in carcinogenesis and suppresses
the activity of Foxo3a transcription factor which is
responsible for controlling cell integrity and homeostasis
[14,16]. In this study, we demonstrate that phosphoryla-
tion and inactivation of the Foxo3a transcription factor
by LMP1 leads to Id1 upregulation. Our finding that
LMP1 expression in primary NPC tumours correlates
with reduction of activated Foxo3a in the nucleus and
increased expression of Id1 corroborates findings
obtained from our in vitro studies. Also, we have found
that the LMP1 induction of Id1 contributes to resistance
to TGFβ-mediated cytostasis and modulate TGFβ-
SMAD-mediated transcription (Figure 8). Although
LMP1 did not interfere with TGFβ-induced SMAD phos-
phorylation, it impaired SMAD-dependent transcription
and suppressed induction of the TGFβ-induced growth
inhibitory protein p21. TGFβ is known to negatively reg-
ulate Id1 transcription through a mechanism involving
SMAD3 activation and induction of the transcription
repressor, ATF3 [8,9]. Here, we report that LMP1 inhibits
basal and TGFβ-induced ATF3 expression. Suppression
of ATF3 by LMP1 abolishes the repressive effect of TGFβ
to Id1 expression (Figure 8). Our current findings provide
new insights into the mechanism by which LMP1 coun-
teracts the cytostatic action of TGFβ and underscore the
importance of Id1 in LMP1-mediated cell transforma-
tion.
Id1 proteins are important regulators of cellular differ-
entiation and cell cycle progression. Over-expression of
Id1 has been widely observed in human cancers where it
may play a critical role in tumourigenesis and cancer pro-
gression [7]. Previous studies have demonstrated upregu-
lation of Id1 by LMP1 in culture epithelial cell lines
[16,17]. Here, an examination of NPC primary tumours
revealed a positive correlation between LMP1 and Id1
expression in NPC cells. In a recent report, Raab-Traub
and colleagues have established that silencing Id1 affects
the growth of LMP1-transformed and parental Rat-1
fibroblasts [15]. However, the precise contribution of Id1
to LMP1-mediated transformation is not clear. In the
present study, we reveal that Id1 increased cell prolifera-
tion and conferred resistance to TGFβ-mediated cell
cycle arrest in nasopharyngeal epithelial cells. Silencing
Id1 by shRNA abolished LMP1-mediated cellular growth
advantage and TGFβ resistance. These findings identify
the important contribution of Id1 in cell growth control
and resistance to TGFβ, and suggest that the induction of
Id1 by LMP1 plays a key role in epithelial cell growth
transformation.
TGFβ-induced cytostasis is mediated at least in part by
SMAD-dependent transcriptional regulation. Activated
SMAD complexes cooperate with various transcription
factors to regulate the expression of TGFβ target genes
involved in growth inhibition and apoptosis [8,9]. In this
study, we found that silencing Id1 diminishes the ability
of LMP1 to inhibit TGFβ-mediated SMAD transcrip-
Figure 6 LMP1 suppresses the expression of ATF3 in a dose de-
pendent manner. NP69 cells were transfected with various doses of 
LMP1 expression vector. Forty-eight hours post-transfection, cells were 
harvested and immunoblotting performed for the ATF3 protein. Rela-
tive protein expression was calculated using densitometry with the 
control set at 1.
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tional activity, indicating that Id1 plays an essential role in
this inhibition. Id1 proteins contain a HLH domain that
allows them to negatively regulate bHLH transcription
factor family members. Although the mechanism of Id1
in suppressing SMAD transcriptional activity is not clear,
it is possible that Id1 interferes certain bHLH transcrip-
tion factors involved in SMAD-mediated transcription.
In fact, a similar scenario has recently been reported
showing that an Id-like HLH protein, human homologue
of Maid (HHM) suppresses TGFβ-mediated cytostasis
and TGFβ-induced expression of PAI-1, PDGF-β and p21
by inhibiting the binding of Olig to Smad2/3 [21]. Olig is
a bHLH transcription factor involved in TGFβ-SMAD
mediated transcription.
The cyclin dependent kinase inhibitor p21 protein is
one of the major TGFβ-activated targets responsible for
cell growth inhibition. Our previous report showed that
p21 protein expression is suppressed in LMP1-expressing
nasopharyngeal epithelial cells [22]. Other workers have
also found that LMP1 inhibits both basal and SMAD-
induced activity of the p21 promoter [12]. Here, we fur-
ther confirm that LMP1 suppresses the expression of
TGFβ-induced p21 protein. Although the mechanism of
p21 suppression by LMP1 is not clear, it may be associ-
ated with Id1 induction as several reports indicate that
Id1 is able to restrain p21 [18,23]. The impact of Id1 on
SMAD mediated p21 expression is clearly an area worthy
of further investigation.
TGFβ-activated SMAD proteins interact with a large
number of DNA binding cofactors, coactivators, and
corepressors, to target different genes with high affinity
and specificity. The outcome of TGFβ-induced effects is
determined by the availability of activated SMAD pro-
teins as well as DNA binding transcriptional factors. Pre-
vious reports have found that LMP1 does not affect
degradation and nuclear localisation of the SMAD pro-
tein [12]. LMP1 also fails to affect the formation of
S MAD  h e t e r o m e r s  as  w e l l  as  D N A  b i n d i n g  a ct i vi t y  o f
SMAD protein [12,13]. Therefore, it is not surprising we
find that the inhibitory effect of LMP1 on transcriptional
activity is independent of SMAD phosphorylation. This
also suggest that the suppressive effect of LMP1 on
SMAD transcriptional function is not due to inhibition of
TGFβ-activated SMAD signalling and may be owing to
repression of the transcriptional cofactors involved in
SMAD-mediated transcription. Here, we show that
LMP1 modulates expression of transcription repressor
Figure 7 Immunohistochemical examination of NPC and normal nasopharyngeal epithelium (Normal NP) specimens for LMP1, Id1 and 
Foxo3a expression. Intensive nuclear staining for Foxo3a was observed in normal NP epithelium with weak expression of Id1. In NPC tumour T1 
which expresses high level of LMP1, strong Id1 expression and weak nuclear staining of Foxo3a was observed. In NPC tumour T3 which shows weak 
LMP1 expression, strong nuclear staining of Foxo3a and weak Id1 detection was observed.
LMP1
Foxo3a
NPC
T1 T2 Normal NP
ID1
T3Lo et al. Molecular Cancer 2010, 9:155
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ATF3 that cooperates with SMADs to regulate gene tran-
scription.
During TGFβ-mediated cytostasis, TGFβ-mediated
SMAD signalling also results in the transcriptional
repression of the growth promoting genes inducing c-
Myc, Id1, Id2 and Id3[8,9]. In response to TGFβ stimula-
tion, SMAD signalling rapidly induces ATF3 expression.
ATF3 then associates with SMAD complex to target Id1
for transcriptional repression. Dominant-negative ATF3,
w h i c h  i s  a b l e  t o  c o m p e t e  w i t h  e n d o g e n o u s  A T F 3  f o r
binding to SMAD3 and the Id1 promoter has been found
to abolish Id1 transcriptional repression by TGFβ [20].
This indicates that ATF3 is necessary for TGFβ-mediated
Id1 repression. In the absence of ATF3, TGFβ-activated
SMAD3 binds to Id1 promoter directly, leading to Id1
upregulation [20]. In this study, we found that ATF3 pro-
tein expression is suppressed by LMP1 resulting in pro-
longed induction of Id1 by TGFβ. Upregulation of Id1 by
TGFβ has been reported in various cell types including
fibroblasts, endothelial cells, renal epithelial cells, and
hepatic stellate cells [24-27]. The possible association
with the absence of ATF3 in these cell types awaits fur-
ther investigation. In addition to its role in TGFβ-medi-
ated Id1 repression, ATF3 also functions to suppress
tumour growth. Previous studies indicate that overex-
pression of ATF3 results in increased apoptosis of pros-
tate cancer cells, reduced tumour size of colorectal
xenografts in nude mice, and increased apoptosis and
reduced metastatic potential of ovarian cancer cells [28-
30]. The mechanism of ATF3 suppression mediated by
LMP1 will be examined further.
Conclusions
Id1 is a critical downstream target of LMP1 and likely
plays an important role in mediating growth transforma-
tion. Here we show that LMP1 inactivates the function of
Foxo3a leading to the induction of Id1. LMP1 also inhib-
its the expression of the ATF3 transcription repressor,
preventing the suppression of Id1 by TGFβ-mediated
SMAD signalling. The induction of Id1 by LMP1 confers
Figure 8 Proposed model describing the mechanism by which LMP1 suppresses TGFβ-mediated cytostasis.Lo et al. Molecular Cancer 2010, 9:155
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a growth advantage to LMP1-expressing cells, by render-
ing cells refractory to the cytostatic effects of TGFβ. Our
findings provide a possible therapeutic strategy whereby
inactivation of Id1 may lead to sensitisation of LMP1-
positive NPC cells to chemotherapeutic drug induced
apoptosis.
Methods
Cell lines, chemicals and transfection
HEK-293 and HepG2 cells were grown in DMEM
medium (Sigma) supplemented with 10%v/v FBS, and
antibiotics. NP69 nasopharyngeal epithelial cells were
maintained in Keratinocyte-Serum free (KSF) medium
(Invitrogen). Recombinant human TGF-β1 (PeproTech)
and MG132 (Sigma) were used for treatment of cells
when specified. Plasmid transfections were performed
using either Fugene HD (Roche) or TurboFect™ in vitro
Transfection Reagent (Fermentas) according to manufac-
turers' instructions.
DNA constructs
The Id1 (-1695) and (-353) promoter luciferase reporters
were generated by PCR and cloned into the pGL3 basic
vector (Promega). The Id1 shRNA B & C expression vec-
tors were generated by inserting a fragment of synthe-
sised Oligo (Sigma) with the sequence of Id1 coding
region into pSUPER.retro.puro vector (oligoengine). The
sequence of Id1 shRNA B is GATCCCC GCG
CGCTGAAGGCCGGCAATTCAAGAGATTGCCGGC-
CTTCAGCGCGCTTTTTA and Id1 shRNA C is GATC-
CCCGGT GCGCTGTCTGTCTGAGTTCA AGAGA
CTCAGACAGACAGCGCACCTTTTTA. pECE-HA-
Foxo3a was kindly provided by M. Deckert [31], pGL2-
Bim vector is gift of P.J. Coffer [32], GFP-Foxo3a is a gift
from MC Hung [33]. The pGL2-p27kip promoter con-
struct was provided by T Sakai [34]. P3Tplux was pro-
vided by J Massagué Laboratory, Memorial Sloan-
Kettering Cancer Center, New York, USA and
pGL3(CAGA) was kind gift from CS Hill (The Cancer
Research UK London Research Institute, London, UK).
Western blotting analysis
The detailed procedures of Western blotting have been
described previously [35]. Briefly, cells were lysed in RIPA
buffer. Total cell lysates (5-25 μg of protein) were sepa-
rated by 10% SDS-PAGE and then electrophoretically
transferred to nitrocellulose membrane prior to immuno-
blotting. Antibodies specific for Phospho-IκBα (Ser32),
Phospho-Erk1/2 (Ser217/221), phospho-Akt (Ser473),
phospho-Foxo3a (Ser253), Foxo3a and p27 were pur-
chased from Cell Signalling, USA. Antibody specific for
ATF3 was from Abcam. Antibodies to SP-1 and α-tubulin
were purchased from Santa Cruz, USA. Antibodies to
LMP1 were purchased from Dako and β-Actin from
Sigma, UK.
Immunohistochemistry
The expression of LMP1 and Foxo3a in paraffin-embed-
ded NPC specimens was examined by immunohis-
tochemistry as described previously [36]. Primary
antibodies used in this study were anti-LMP1 mouse
monoclonal antibody (DAKO) and anti-Foxo3a rabbit
polyclonal antibody (Cell Signalling).
Luciferase reporter assay
1×105 cells grown in 24-well plates were co-transfected
with 40 ng of luciferase reporter constructs together with
different amounts of expression vectors as indicated in
the text. RSV-β-Gal vector (50 ng) was transfected as an
internal control to normalise for transfection efficiency.
Two days post-transfection, cells were lysed in reporter
lysis buffer (Promega) and then assayed for luciferase and
β-gal activities. For detection of Id promoter activity,
transfected cells were cultured in serum free medium for
6 hrs before harvesting. For detection of TGFβ responsive
promoter activity of pGL3(CAGA) and p3TLux con-
structs, cells were cultured in medium containing 0.2%
FBS and 5 ng/ml TGFβ for 16 hrs prior to harvesting.
Cell Cycle Analysis
Cells (5 × 105) were fixed in ice cold 70% ethanol for 1 hr.
Prior to analysis, fixed cells were washed with PBS,
treated with RNase (1 μg/ml) and stained with propidium
iodide (50 μg/ml) for 30 min at 37°C. Cell cycle analysis
was carried out on a XL-MCL flow cytometer (Beckman-
Coulter) and data analyzed using the MultiCycle AV
DNA Analysis software (Phoenix Flow Systems).
MTT assay
For MTT assay, cells (5×103 per well) were seeded into
96-well plates. One day after cell seeding. TGFβ1 (10ng/
ml) was added. MTT assay was analyzed each 24 hrs by
adding MTT solution (5 mg/ml; 10 μl/well) and cells were
incubated at 37°C for 5 hrs. The culture media were aspi-
rated and DMSO (200 μl/well) was added to dissolve the
formazan crystals. The absorbance was measured at a
wavelength of 570 nm. Each time point was performed in
triplicate. Results are presented as relative growth rate by
dividing the absorbance value of the cells at indicated
time points by the absorbance value of the cells one day
after cell plating. Each data point is represented by the
mean and SD.
Additional material
Additional file 1 Validation of Id1 expression in Id1 shRNA expressing 
NP69 cells. NP69-pLNSX and NP69-LMP1 cells were transduced with pSu-
per.retro control or pSuper.retro-Id1 shRNA B (shId1B), pSuper.retro-Id1 
shRNA C (shId1C) or two shRNA-Id1 constructs (shId1B+C). The sequences 
of Id shRNA B and C are described in Material and Methods. After Puromy-
cin drug selection, Id1 shRNA expressing cells were validated for Id1 expres-
sion by western blotting.Lo et al. Molecular Cancer 2010, 9:155
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